MX2023002482A - Composicion farmaceutica para prevencion y/o tratamiento de prurito por dialisis que comprende antagonista de interleucina 31 (il-31) como ingrediente activo. - Google Patents
Composicion farmaceutica para prevencion y/o tratamiento de prurito por dialisis que comprende antagonista de interleucina 31 (il-31) como ingrediente activo.Info
- Publication number
- MX2023002482A MX2023002482A MX2023002482A MX2023002482A MX2023002482A MX 2023002482 A MX2023002482 A MX 2023002482A MX 2023002482 A MX2023002482 A MX 2023002482A MX 2023002482 A MX2023002482 A MX 2023002482A MX 2023002482 A MX2023002482 A MX 2023002482A
- Authority
- MX
- Mexico
- Prior art keywords
- dialysis
- antagonist
- prevention
- treatment
- active ingredient
- Prior art date
Links
- 102100021596 Interleukin-31 Human genes 0.000 title abstract 3
- 101710181613 Interleukin-31 Proteins 0.000 title abstract 3
- 239000004480 active ingredient Substances 0.000 title abstract 2
- 239000005557 antagonist Substances 0.000 title abstract 2
- 238000000502 dialysis Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title abstract 2
- 208000003251 Pruritus Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/JP2020/032987 WO2022049614A1 (ja) | 2020-09-01 | 2020-09-01 | Ｉｌ－３１アンタゴニストを有効成分として含有する、透析そう痒症の予防用及び／又は治療用医薬組成物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023002482A true MX2023002482A (es) | 2023-03-08 |
Family
ID=73741045
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023002482A MX2023002482A (es) | 2020-09-01 | 2020-09-01 | Composicion farmaceutica para prevencion y/o tratamiento de prurito por dialisis que comprende antagonista de interleucina 31 (il-31) como ingrediente activo. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230391878A1 (OSRAM) |
| EP (1) | EP4209227A4 (OSRAM) |
| JP (2) | JP6799831B1 (OSRAM) |
| KR (2) | KR102800698B1 (OSRAM) |
| CN (1) | CN116096411A (OSRAM) |
| AU (1) | AU2020466800A1 (OSRAM) |
| CA (1) | CA3189847A1 (OSRAM) |
| IL (1) | IL300694A (OSRAM) |
| MX (1) | MX2023002482A (OSRAM) |
| WO (1) | WO2022049614A1 (OSRAM) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016167263A1 (ja) | 2015-04-14 | 2016-10-20 | 中外製薬株式会社 | Ｉｌ－３１アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び／又は治療用医薬組成物 |
| ES3036076T3 (en) | 2015-04-14 | 2025-09-12 | Chugai Pharmaceutical Co Ltd | Pharmaceutical composition for prevention and/or treatment of atopic dermatitis containing il-31 antagonist as active ingredient |
| WO2018156180A1 (en) | 2017-02-24 | 2018-08-30 | Kindred Biosciences, Inc. | Anti-il31 antibodies for veterinary use |
| BR112022006590A2 (pt) | 2019-11-20 | 2022-06-28 | Chugai Pharmaceutical Co Ltd | Preparação contendo anticorpos |
| WO2025167991A1 (zh) * | 2024-02-07 | 2025-08-14 | 武汉人福创新药物研发中心有限公司 | 一种靶向il-31ra的抗体或其抗原结合片段及其应用 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2707189B1 (fr) | 1993-07-09 | 1995-10-13 | Gradient Ass | Procédé de traitement de résidus de combustion et installation de mise en Óoeuvre dudit procédé. |
| JP4334141B2 (ja) | 1998-04-20 | 2009-09-30 | グリカート バイオテクノロジー アクチェンゲゼルシャフト | 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作 |
| CA2369292C (en) | 1999-04-09 | 2010-09-21 | Kyowa Hakko Kogyo Co. Ltd. | Method of modulating the activity of functional immune molecules |
| ATE455852T1 (de) | 1999-06-02 | 2010-02-15 | Chugai Pharmaceutical Co Ltd | Neues hämopoietin rezeptorprotein nr10 |
| EP1332209B1 (en) | 2000-09-08 | 2009-11-11 | Universität Zürich | Collections of repeat proteins comprising repeat modules |
| AU1325102A (en) | 2000-10-16 | 2002-04-29 | Phylos Inc | Protein scaffolds for antibody mimics and other binding proteins |
| US20030157561A1 (en) | 2001-11-19 | 2003-08-21 | Kolkman Joost A. | Combinatorial libraries of monomer domains |
| JP2002338476A (ja) * | 2001-05-21 | 2002-11-27 | Health Factor Kenkyusho:Kk | 腎透析に伴う痒みの予防治療剤 |
| JP4511349B2 (ja) | 2002-01-18 | 2010-07-28 | ザイモジェネティクス，インコーポレイティド | サイトカイン受容体ｚｃｙｔｏｒ１７マルチマー |
| EP1713325A2 (en) | 2004-02-12 | 2006-10-25 | Lexicon Genetics Incorporated | Gene disruptions, compositions and methods relating thereto |
| EP1671642A1 (en) | 2004-12-15 | 2006-06-21 | Universite D'angers | Compositions comprising (ant)agonists of oncostatin M (OSM), IL-31 and IFN-gamma for modulating keratinocyte migration and functions via a receptor containing OSMRbeta as a subunit, and applications thereof. |
| EP1856150A2 (en) | 2005-02-14 | 2007-11-21 | ZymoGenetics, Inc. | Methods of treating diseases which are mediated by cutaneous lymphocyte antigen positive cells |
| WO2006088855A1 (en) | 2005-02-14 | 2006-08-24 | Zymogenetics, Inc. | Methods of treating skin disorders using an il-31ra antagonist |
| JP5065253B2 (ja) | 2005-05-06 | 2012-10-31 | ザイモジェネティクス， インコーポレイテッド | Ｉｌ−３１モノクローナル抗体とその使用法 |
| CN101589060A (zh) * | 2006-01-10 | 2009-11-25 | 津莫吉尼蒂克斯公司 | 使用il-31拮抗剂在神经元性组织中治疗疼痛和炎症的方法 |
| MX2008008831A (es) * | 2006-01-10 | 2009-03-04 | Zymogenetics Inc | Metodos para tratar dolor e inflamacion en tejidos neuronales usando antagonistas il-31. |
| PE20080333A1 (es) | 2006-06-08 | 2008-06-15 | Chugai Pharmaceutical Co Ltd | Agentes para prevenir o tratar enfermedades inflamatorias |
| DK2594586T3 (en) | 2006-09-01 | 2014-11-17 | Zymogenetics Inc | Monoclonal il-31 antibodies and methods of use thereof |
| MX337081B (es) | 2007-12-05 | 2016-02-10 | Chugai Pharmaceutical Co Ltd | Anticuerpo anti-nr10 y su uso. |
| MY162546A (en) | 2007-12-05 | 2017-06-15 | Chugai Pharmaceutical Co Ltd | Therapeutic agent for pruritus |
| AU2008333131B2 (en) | 2007-12-07 | 2013-10-24 | Merck Serono S/A | Humanized antibody molecules specific for IL-31 |
| JP2010210772A (ja) * | 2009-03-13 | 2010-09-24 | Dainippon Screen Mfg Co Ltd | 液晶表示装置の製造方法 |
| JP5650871B1 (ja) * | 2013-06-28 | 2015-01-07 | 中外製薬株式会社 | そう痒を伴う疾患に罹患した患者のｉｌ−３１アンタゴニストによる治療に対する応答を予測する方法 |
| WO2015025767A1 (ja) * | 2013-08-21 | 2015-02-26 | 久光製薬株式会社 | 貼付剤 |
| US20190135804A1 (en) * | 2017-11-03 | 2019-05-09 | The United States Of America,As Represented By The Secretary,Department Of Health And Human Services | Compositions and methods for the inhibition of pruritus |
| KR102156932B1 (ko) * | 2017-11-23 | 2020-09-17 | 주식회사 헬릭스미스 | 천연추출물을 포함하는 소양증의 예방 또는 치료용 조성물 |
| WO2019229525A2 (en) * | 2018-04-25 | 2019-12-05 | Kiniksa Pharmaceuticals, Ltd. | TREATMENT OF SKIN DISEASES OR DISORDERS BY DELIVERY OF ANTI-OSMRβ ANTIBODY |
-
2020
- 2020-09-01 JP JP2020551453A patent/JP6799831B1/ja active Active
- 2020-09-01 WO PCT/JP2020/032987 patent/WO2022049614A1/ja not_active Ceased
- 2020-09-01 AU AU2020466800A patent/AU2020466800A1/en active Pending
- 2020-09-01 KR KR1020217018823A patent/KR102800698B1/ko active Active
- 2020-09-01 US US18/023,246 patent/US20230391878A1/en active Pending
- 2020-09-01 IL IL300694A patent/IL300694A/en unknown
- 2020-09-01 EP EP20952354.7A patent/EP4209227A4/en active Pending
- 2020-09-01 CA CA3189847A patent/CA3189847A1/en active Pending
- 2020-09-01 MX MX2023002482A patent/MX2023002482A/es unknown
- 2020-09-01 KR KR1020207030800A patent/KR102269716B1/ko active Active
- 2020-09-01 CN CN202080103639.6A patent/CN116096411A/zh active Pending
- 2020-11-11 JP JP2020187708A patent/JP7548784B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| IL300694A (en) | 2023-04-01 |
| KR102800698B1 (ko) | 2025-04-24 |
| KR102269716B1 (ko) | 2021-06-28 |
| KR20230048233A (ko) | 2023-04-11 |
| CN116096411A (zh) | 2023-05-09 |
| EP4209227A1 (en) | 2023-07-12 |
| JP6799831B1 (ja) | 2020-12-16 |
| US20230391878A1 (en) | 2023-12-07 |
| JP2022041802A (ja) | 2022-03-11 |
| AU2020466800A1 (en) | 2023-03-23 |
| CA3189847A1 (en) | 2022-03-10 |
| JPWO2022049614A1 (OSRAM) | 2022-03-10 |
| WO2022049614A1 (ja) | 2022-03-10 |
| EP4209227A4 (en) | 2024-05-29 |
| JP7548784B2 (ja) | 2024-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023002482A (es) | Composicion farmaceutica para prevencion y/o tratamiento de prurito por dialisis que comprende antagonista de interleucina 31 (il-31) como ingrediente activo. | |
| BR112021009595A2 (pt) | Terapia de combinação incluindo um inibidor de krasg12c e um ou mais agentes farmaceuticamente ativos adicionais para o tratamento de cânceres | |
| BR112022000503A2 (pt) | Compostos úteis para tratar infecções por vírus influenza | |
| MX2019014104A (es) | Compuesto novedoso de bifenilo o sal del mismo. | |
| CL2021000741A1 (es) | Composiciones plaguicidas sinérgicas y métodos para distribución de ingredientes activos insecticidas | |
| NZ735820A (en) | Compositions comprising a combination of an anti-pd-1 antibody and another antibody | |
| BR112019008431A2 (pt) | aplicação de (s)-norcetamina e sal da mesma como fármaco | |
| BR112014016672A8 (pt) | compostos de carbamato, seu uso e composição farmaceuticamente aceitável os compreendendo | |
| CR20150505A (es) | Derivado de dihidropiridazin-3,5-diona | |
| CL2021001739A1 (es) | Inhibidores de la proteína de activación de fibroblastos. | |
| CO2019002246A2 (es) | Compuesto heterocíclico nitrogenado bicíclico | |
| BR112022002289A2 (pt) | Composições de curativo líquido e seus usos veterinários | |
| MX2021010144A (es) | Formulaciones farmaceuticas. | |
| BR112021025732A2 (pt) | Inibidores macrocíclicos de mcl-1 | |
| CO2017011778A2 (es) | Un inhibidor de la actividad del csf-1r y composiciones farmaceuticas que lo comprenden | |
| MX388378B (es) | Compuestos de aza-indazol para usar en lesiones de tendones y/o ligamentos. | |
| ES3046835T3 (en) | Phenyl carbamate compounds for use in preventing or treating epilepsy or epilepsy-related syndrome | |
| MX2020012989A (es) | Agente terapeutico para la fibrosis. | |
| MX2023010491A (es) | Composicion farmaceutica para el tratamiento o la prevencion de la miastenia gravis. | |
| BR112017004505A2 (pt) | agente terapêutico e método para prevenção e/ou tratamento de incontinência urinária, e, composto ou um sal do mesmo. | |
| MX381311B (es) | Método para el tratamiento de prurito y/o comezón. | |
| BR112021022194A2 (pt) | Formulações líquidas para dosagem oral de metilnaltrexona | |
| BR112017021380A2 (pt) | composto, combinação, formulação farmacêutica, método de extermínio e/ou prevenção do crescimento de um protozoário, e, uso de composto | |
| BR112017023425A2 (pt) | combinações terapêuticas de terapias antivirais e anti-inflamatórias | |
| MX2019008338A (es) | Composicion farmaceutica que contiene sulglicotido o una sal farmaceuticamente aceptable del mismo para la prevencion o tratamiento del ojo seco. |